Clinical trial results:
A Prospective, International, Multi-Centric, Open-Label Study to Assess the Efficacy of an Extended Injection Interval schedule of Lanreotide Autogel 120 Mg In Acromegalic Subjects who are Biochemically controlled on the Long Term Treatment with Octreotide Lar 10 or 20 mg

Summary

EudraCT number	2007-005838-37
Trial protocol	SE FR DK NL FI LV GR
Global end of trial date	20 May 2013

Results information

Result version number	v1 (current)
This version publication date	16 March 2016
First version publication date	16 March 2016

Trial information

Trial identification

Sponsor protocol code	A-38-52030-214

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Ipsen Pharma
Sponsor organisation address	65 quai Georges Gorse, Boulogne Billancourt Cedex, France, 92650
Public contact	Medical Director, Clinical Endocrinology and Metabolism, Ipsen, 0033 158335000, clinical.trials@ipsen.com
Scientific contact	Medical Director, Clinical Endocrinology and Metabolism, Ipsen, 0033 158335000, clinical.trials@ipsen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 May 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 May 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of extended injection intervals (every 6 or 8 weeks) of lanreotide Autogel 120 mg in the control of insulin-like growth factor-1 (IGF-1) levels in adult subjects with acromegaly who are biochemically controlled with octreotide LAR (10 or 20 mg).

Protection of trial subjects:

This clinical study was designed and implemented and reported in accordance with the International Conference on Harmonisation (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.

Background therapy:

Adult subjects with acromegaly controlled with Octreotide long acting repeatable (Oct-LAR) 10 or 20 mg every 28 days for at least 6 months

Evidence for comparator: -

Actual start date of recruitment	06 October 2008
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	2 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Norway: 1
Country: Number of subjects enrolled	Poland: 12
Country: Number of subjects enrolled	Romania: 1
Country: Number of subjects enrolled	Russian Federation: 20
Country: Number of subjects enrolled	Serbia: 15
Country: Number of subjects enrolled	Sweden: 4
Country: Number of subjects enrolled	Brazil: 15
Country: Number of subjects enrolled	Denmark: 2
Country: Number of subjects enrolled	Finland: 3
Country: Number of subjects enrolled	France: 14
Country: Number of subjects enrolled	Greece: 9
Country: Number of subjects enrolled	Korea, Republic of: 17
Country: Number of subjects enrolled	Latvia: 10

Worldwide total number of subjects	124
EEA total number of subjects	57

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	105
From 65 to 84 years	19
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study initiation date: 06-Oct-2008. Study completion date: 20-May-2013. Screened subjects were 128 and screen failure subjects were 4. Subjects treated were 124 and subjects withdrawn early were 17. Subjects completed the study were 107.

Pre-assignment

Screening details: -

Pre-assignment period milestones

Number of subjects started	128[1]
Number of subjects completed	124

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Does not meet Entry Criteria: 4

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Pre-assignment period includes screen failure subjects

Period 1

Period 1 title	Treatment Phase (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase 1: Lanreotide Autogel 120 mg

Arm description:

Subjects in phase 1 received 5 injections of Lanreotide Autogel 120 mg subcutaneously (SC) at baseline and weeks 6, 12, 18 and 24. Baseline and week 24 injections were administered in the investigational centre, whereas the patient could receive weeks 6, 12 and 18 injections at home as part of the subject's normal medical care, completing details of the injection in the diary cards provided.

Arm type	Experimental
Investigational medicinal product name	Lanreotide Autogel
Investigational medicinal product code	
Other name	Oct-LAR
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg subcutaneous (SC) injection

Arm title	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks

Arm description:

Subjects with IGF-1 levels >100% to ≤130% of ULN at week 24 were assigned to group A. These subjects received 5 injections of Lanreotide Autogel 120 mg at 4-week intervals from week 24 up to week 48.

Arm type	Experimental

Investigational medicinal product name	Lanreotide Autogel
Investigational medicinal product code	
Other name	Oct-LAR
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg subcutaneous (SC) injection

Arm title	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks

Arm description:

Subjects with IGF-1 levels >50% to ≤100% of ULN at week 24 were assigned to group B. These subjects received 3 injections of Lanreotide Autogel 120 mg at 6-week intervals from week 24 up to week 48.

Arm type	Experimental
Investigational medicinal product name	Lanreotide Autogel
Investigational medicinal product code	
Other name	Oct-LAR
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg subcutaneous (SC) injection

Arm title	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks

Arm description:

Subjects with IGF-1 levels ≤50% of ULN at week 24 were assigned to group C. These subjects received 2 injections of Lanreotide Autogel 120 mg at 8-week intervals from week 24 up to week 48.

Arm type	Experimental
Investigational medicinal product name	Lanreotide Autogel
Investigational medicinal product code	
Other name	Oct-LAR
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg subcutaneous (SC) injection

Number of subjects in period 1	Phase 1: Lanreotide Autogel 120 mg	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks
Started	15	13	70
Completed	0	13	68
Not completed	15	0	2
Consent withdrawn by subject	5	-	1
Adverse event, non-fatal	7	-	1
Does not meet Entry Criteria	1	-	-
Lack of efficacy	1	-	-
Protocol deviation	1	-	-

Number of subjects in period 1	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8

	weeks
Started	26
Completed	26
Not completed	0
Consent withdrawn by subject	-
Adverse event, non-fatal	-
Does not meet Entry Criteria	-
Lack of efficacy	-
Protocol deviation	-

Baseline characteristics

Reporting groups	
Reporting group title	Phase 1: Lanreotide Autogel 120 mg
Reporting group description:	
Subjects in phase 1 received 5 injections of Lanreotide Autogel 120 mg subcutaneously (SC) at baseline and weeks 6, 12, 18 and 24. Baseline and week 24 injections were administered in the investigational centre, whereas the patient could receive weeks 6, 12 and 18 injections at home as part of the subject's normal medical care, completing details of the injection in the diary cards provided.	
Reporting group title	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks
Reporting group description:	
Subjects with IGF-1 levels >100% to ≤130% of ULN at week 24 were assigned to group A. These subjects received 5 injections of Lanreotide Autogel 120 mg at 4-week intervals from week 24 up to week 48.	
Reporting group title	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks
Reporting group description:	
Subjects with IGF-1 levels >50% to ≤100% of ULN at week 24 were assigned to group B. These subjects received 3 injections of Lanreotide Autogel 120 mg at 6-week intervals from week 24 up to week 48.	
Reporting group title	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks
Reporting group description:	
Subjects with IGF-1 levels ≤50% of ULN at week 24 were assigned to group C. These subjects received 2 injections of Lanreotide Autogel 120 mg at 8-week intervals from week 24 up to week 48.	

Reporting group values	Phase 1: Lanreotide Autogel 120 mg	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks
Number of subjects	15	13	70
Age categorical Units: Subjects			
Adults (18-64 years)	11	11	61
Adults (65-84 years)	4	2	9
Age continuous			
Overall analysis (All subjects) for age continuous at baseline value is arithmetic mean (Standard Deviation) = 54.4 (± 10.9) years			
Units: years			
arithmetic mean	55.2	55	53.2
standard deviation	± 15.3	± 10.1	± 10.4
Gender categorical Units: Subjects			
Female	9	8	41
Male	6	5	29
BMI			
Overall analysis (All subjects) for BMI at baseline value is arithmetic mean (Standard Deviation) = 28.8 (± 5.6) kg/m^2			
Units: kg/m^2			
arithmetic mean	28.4	29.2	29.5
standard deviation	± 2.9	± 4.1	± 6.5

Reporting group values	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks	Total	

Number of subjects	26	124	
Age categorical Units: Subjects			
Adults (18-64 years)	22	105	
Adults (65-84 years)	4	19	
Age continuous			
Overall analysis (All subjects) for age continuous at baseline value is arithmetic mean (Standard Deviation) = 54.4 (± 10.9) years			
Units: years			
arithmetic mean	57		
standard deviation	± 9.8	-	
Gender categorical Units: Subjects			
Female	20	78	
Male	6	46	
BMI			
Overall analysis (All subjects) for BMI at baseline value is arithmetic mean (Standard Deviation) = 28.8 (± 5.6) kg/m^2			
Units: kg/m^2			
arithmetic mean	27		
standard deviation	± 4.3	-	

End points

End points reporting groups

Reporting group title	Phase 1: Lanreotide Autogel 120 mg
Reporting group description:	
Subjects in phase 1 received 5 injections of Lanreotide Autogel 120 mg subcutaneously (SC) at baseline and weeks 6, 12, 18 and 24. Baseline and week 24 injections were administered in the investigational centre, whereas the patient could receive weeks 6, 12 and 18 injections at home as part of the subject's normal medical care, completing details of the injection in the diary cards provided.	
Reporting group title	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks
Reporting group description:	
Subjects with IGF-1 levels >100% to ≤130% of ULN at week 24 were assigned to group A. These subjects received 5 injections of Lanreotide Autogel 120 mg at 4-week intervals from week 24 up to week 48.	
Reporting group title	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks
Reporting group description:	
Subjects with IGF-1 levels >50% to ≤100% of ULN at week 24 were assigned to group B. These subjects received 3 injections of Lanreotide Autogel 120 mg at 6-week intervals from week 24 up to week 48.	
Reporting group title	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks
Reporting group description:	
Subjects with IGF-1 levels ≤50% of ULN at week 24 were assigned to group C. These subjects received 2 injections of Lanreotide Autogel 120 mg at 8-week intervals from week 24 up to week 48.	
Subject analysis set title	Overall Study
Subject analysis set type	Full analysis
Subject analysis set description:	
Lanreotide Autogel 120 mg: Phase 1 and 2	
Subject analysis set title	Phase 1 Only: Lanreotide Autogel 120 mg
Subject analysis set type	Full analysis
Subject analysis set description:	
Only 15 subjects participated only in phase 1 and did not move on to phase 2. The other entered in phase 2 according to IGF-1 level. Subjects in phase 1 received 5 injections of Lanreotide Autogel 120 mg subcutaneously (SC) at baseline and weeks 6, 12, 18 and 24. Baseline and week 24 injections were administered in the investigational centre, whereas the patient could receive weeks 6, 12 and 18 injections at home as part of the subject's normal medical care, completing details of the injection in the diary cards provided.	
Subject analysis set title	Phase 2 (Group A): Lanreotide Autogel 120 mg Every 4 Weeks
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects with IGF-1 levels >100% to ≤130% of ULN at week 24 were assigned to group A. These subjects received 5 injections of Lanreotide Autogel 120 mg at 4-week intervals from week 24 up to week 48.	
Subject analysis set title	Phase 2 (Group B): Lanreotide Autogel 120 mg Every 6 Weeks
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects with IGF-1 levels >50% to ≤100% of ULN at week 24 were assigned to group B. These subjects received 3 injections of Lanreotide Autogel 120 mg at 6-week intervals from week 24 up to week 48.	
Subject analysis set title	Phase 2 (Group C): Lanreotide Autogel 120 mg Every 8 Weeks
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects with IGF-1 levels ≤50% of ULN at week 24 were assigned to group C. These subjects received 2 injections of Lanreotide Autogel 120 mg at 8-week intervals from week 24 up to week 48.	

Primary: Percentage of Subjects Having Maintained Their Injection Interval Schedule of Six Weeks or Increased Their Injection Interval to Eight Weeks Whilst Keeping Their Normalised Insulin Growth Factor (IGF-1) Levels (Age and Sex Adjusted)

End point title	Percentage of Subjects Having Maintained Their Injection Interval Schedule of Six Weeks or Increased Their Injection Interval to Eight Weeks Whilst Keeping Their Normalised Insulin Growth Factor (IGF-1) Levels (Age and Sex Adjusted)[1]

End point description:

A subject was responder if he maintained his injection interval schedule of 6 weeks or increased his injection interval to eight weeks whilst keeping his normalised IGF-1 level (age and sex adjusted) at the end of the study (Week 48)

Intention to Treat (ITT) population: All patients having received ≥1 study drug dose. Modified ITT (MITT) population: All subjects in the ITT population for whom group allocation was performed (included in Phase 2)

N = Number of subjects at the visit

End point type	Primary

End point timeframe:

At week 48 (End of Study)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical anaylsis is not done for this endpoint

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Percentage of Subjects				
number (confidence interval 95%)				
Intention-to-Treat (N=124)	75.8 (68.3 to 83.3)			
Modified Intention-to-Treat (N=109)	86.2 (79.8 to 92.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Normalised IGF 1 Levels (Age and Sex Adjusted)

End point title	Percentage of Subjects With Normalised IGF 1 Levels (Age and Sex Adjusted)

End point description:

The criterion for a subject is satisfied if he has a normalised IGF-1 level (age and sex adjusted) at week 24.

ITT population. N = Number of subjects at the visit.

End point type	Secondary

End point timeframe:

At week 24

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Percentage of subjects				
number (confidence interval 95%)				
Intention-to-Treat (N=124)	88.7 (83.1 to 94.3)			
Modified intention-to-Treat (N=109)	100 (100 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Having Maintained an Injection Interval of Six Weeks or Increasing Their Injection Interval to Eight Weeks

End point title	Percentage of Subjects Having Maintained an Injection Interval of Six Weeks or Increasing Their Injection Interval to Eight Weeks

End point description:

The criterion for a subject is satisfied if he maintained an injection interval of six weeks or increasing his injection interval to eight weeks during Phase 2 of the study.

ITT population. N= Number of subjects at the visit.

End point type	Secondary

End point timeframe:

During phase 2 of the study (up to Week 48)

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Percentage of subjects				
number (confidence interval 95%)				
Intention-to-Treat (N=124)	78.2 (71 to 85.5)			
Modified Intention-to-Treat (N=109)	88.1 (82 to 94.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Extend Their Injection Interval to Eight Weeks During Phase 2 of the Study, Whilst Maintaining Normalised IGF-1 Levels

End point title	Percentage of Subjects Who Extend Their Injection Interval to Eight Weeks During Phase 2 of the Study, Whilst Maintaining Normalised IGF-1 Levels

End point description:

The criterion for a subject is satisfied if he extended his injection interval to eight weeks during Phase 2 of the study, whilst maintaining normalised IGF-1 levels at Week 48.

ITT population. N = Number of subjects at the visit.

End point type	Secondary

End point timeframe:

At week 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Percentage of subjects				
number (confidence interval 95%)				
Intention-to-Treat (N=124)	20.2 (13.1 to 27.2)			
Modified Intention-to-Treat (N=109)	22.9 (15 to 30.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in IGF-1 Values [Expressed as % of Upper Limit of Normal (ULN)], Overall and by Injection Interval

End point title	Mean Change From Baseline in IGF-1 Values [Expressed as % of Upper Limit of Normal (ULN)], Overall and by Injection Interval[2]

End point description:

IGF-1 change from Baseline to Week 48 = Mean IGF-1 level at Week 48 - Mean IGF-1 level at Baseline.

MITT population. One subject (Group B) had missing IGF-1 value at Week 48. One subject (Group A) had missing IGF-1 value at Baseline.

End point type	Secondary

End point timeframe:

At baseline (visit 1) and week 48

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Comparisons are done only in phase 2 groups [Phae 2 Groups A,B and C]

End point values	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	67	25	
Units: Percentage of ULN				
arithmetic mean (standard deviation)	-1.7 (± 18.55)	5.74 (± 30.48)	-4.33 (± 28.14)	

Statistical analyses

Statistical analysis title	Phase 2: Group A versus B

Statistical analysis description:

Phase 2 (Group A): Lanreotide Autogel 120 mg Every 4 Weeks
Phase 2 (Group B): Lanreotide Autogel 120 mg Every 6 Weeks

One subject (Group B) had missing IGF-1 value at Week 48. One subject (Group A) had missing IGF-1 value at Baseline.

Comparison groups	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks v Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013 [3]
Method	ANCOVA

Notes:

[3] - Adjusted mean difference [95% CI] = 18.69 [7.46 to 29.91]

Statistical analysis title	Phase2: Group C versus B

Statistical analysis description:

Phase 2 (Group B): Lanreotide Autogel 120 mg Every 6 Weeks
Phase 2 (Group C): Lanreotide Autogel 120 mg Every 8 Weeks

Comparison groups	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks v Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [4]
Method	ANCOVA

Notes:

[4] - Adjusted mean difference [95% CI] = -23.97 [-32.12 to [-15.81]

Statistical analysis title	Phase2: Group A versus C

Statistical analysis description:

Phase 2 (Group A): Lanreotide Autogel 120 mg Every 4 Weeks

Phase 2 (Group C): Lanreotide Autogel 120 mg Every 8 Weeks

Comparison groups	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks v Phase 2 (Group C): Lanreotide Autogel 120 mg every 8

	weeks
Number of subjects included in analysis	37
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [5]
Method	ANCOVA

Notes:

[5] - Adjusted mean difference [95% CI] = 42.65 [29.48 to 55.82]

Secondary: Treatment Group (A, B or C) Mean Baseline IGF-1 Levels (Expressed as % of ULN) in Subjects Who Maintained Normalised IGF-1 Values at Week 48. Comparisons Will be Made as Follows: A Versus B, A Versus C, A Versus (B+C) and B Versus C

End point title	Treatment Group (A, B or C) Mean Baseline IGF-1 Levels (Expressed as % of ULN) in Subjects Who Maintained Normalised IGF-1 Values at Week 48. Comparisons Will be Made as Follows: A Versus B, A Versus C, A Versus (B+C) and B Versus C[6]

End point description:

MITT population.

One subject in Group A had missing IGF-1 value at baseline. One subject in Group B had missing IGF-1 value at week 48 and two subjects did not attend week 48 (early withdrawal). One subject in Group C had missing IGF-1 value at week 48.

End point type	Secondary

End point timeframe:

At baseline (visit 1)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Comparisons are done only in phase 2 groups [A versus B, A versus C, A versus (B+C) and B versus C]

End point values	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks	Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	67	25	
Units: Percentage of ULN				
arithmetic mean (confidence interval 95%)	98.69 (89.4 to 108)	67.75 (60.4 to 75.1)	51.3 (41.1 to 61.5)	

Statistical analyses

Statistical analysis title	Phase 2: Group A versus Group B

Statistical analysis description:

Phase 2 (Group A): Lanreotide Autogel 120 mg Every 4 Weeks
Phase 2 (Group B): Lanreotide Autogel 120 mg Every 6 Weeks

Comparison groups	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks v Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks

Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0009 [7]
Method	t-test, 2-sided

Notes:

[7] - Difference (95% CI) = 30.94% (13.12% to 48.75%)

Statistical analysis title	Phase 2: Group A versus Group C

Statistical analysis description:

Phase 2 (Group A): Lanreotide Autogel 120 mg Every 4 Weeks
Phase 2 (Group C): Lanreotide Autogel 120 mg Every 8 Weeks

Comparison groups	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks v Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks
Number of subjects included in analysis	37
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [8]
Method	t-test, 2-sided

Notes:

[8] - Difference (95% CI) = 47.40% (31.67% to 63.12%)

Statistical analysis title	Group A versus (B + C)

Statistical analysis description:

Phase 2 (Group A): Lanreotide Autogel 120 mg Every 4 Weeks
Phase 2 (Group B): Lanreotide Autogel 120 mg Every 6 Weeks
Phase 2 (Group C): Lanreotide Autogel 120 mg Every 8 Weeks

Comparison groups	Phase 2 (Group A): Lanreotide Autogel 120 mg every 4 weeks v Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks v Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [9]
Method	t-test, 2-sided

Notes:

[9] - Difference (95% CI) = 35.41% (18.11% to 52.71%)

Statistical analysis title	Phase 2: Group B versus C

Statistical analysis description:

Phase 2 (Group B): Lanreotide Autogel 120 mg Every 6 Weeks
Phase 2 (Group C): Lanreotide Autogel 120 mg Every 8 Weeks

Comparison groups	Phase 2 (Group B): Lanreotide Autogel 120 mg every 6 weeks v Phase 2 (Group C): Lanreotide Autogel 120 mg every 8 weeks

Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.017 [10]
Method	t-test, 2-sided

Notes:

[10] - Difference (95% CI) = 16.46% (3.01% to 29.91%)

Secondary: Mean Baseline IGF-1 Levels (Expressed as % of ULN) in All Groups (A, B and C) Versus Mean Baseline IGF-1 Levels (Expressed as % of ULN) in Subjects With Uncontrolled IGF-1 Levels at Week 24

End point title	Mean Baseline IGF-1 Levels (Expressed as % of ULN) in All Groups (A, B and C) Versus Mean Baseline IGF-1 Levels (Expressed as % of ULN) in Subjects With Uncontrolled IGF-1 Levels at Week 24

End point description:

ITT population.

n = Number of subjects at the visit.

These subjects entered in phase 2.

One subject was not included in this analysis because IGF-1 was lower than 130% at week 24 but not in the second phase and one subject in group A had missing IGF-1 value at baseline.

End point type	Secondary

End point timeframe:

At baseline (Visit 1)

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	122			
Units: Percentage of ULN				
number (confidence interval 95%)				
Uncontrolled IGF-1 levels at Week 24 (n=14)	95.92 (50.3 to 141.5)			
Normalized IGF-1 levels at Week 24 (A+B+C) (n=108)	67.49 (61.8 to 73.2)			
Difference in Mean Baseline	28.43 (6.83 to 50.03)			

Statistical analyses

No statistical analyses for this end point

Secondary: Symptoms of Acromegaly (Headache, Excessive Perspiration, Fatigue, Soft Tissue Swelling and Arthralgia)

End point title	Symptoms of Acromegaly (Headache, Excessive Perspiration, Fatigue, Soft Tissue Swelling and Arthralgia)

End point description:

Acromegaly symptoms were assessed by the patients using the Patient Assessed Acromegaly Symptom

Questionnaire (PASQ) scale ranging from 0 (No symptoms) to 8 (Severe, incapacitating symptoms).

Phase 1 in week 24: 3

Phase 2 (Group A) in week 24: 13

Phase 2 (Group B) in week 24: 69

Phase 2 (Group C) in week 24: 25

Phase 2 (Group A) in week 48: 13

Phase 2 (Group B) in week 48: 68

Phase 2 (Group C) in week 48: 26

End point type	Secondary

End point timeframe:
At baseline, week 24 and week 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Baseline - Headache	2 (± 1.95)			
Baseline - Excessive perspiration	2.34 (± 2.3)			
Baseline - Fatigue	3.4 (± 2.4)			
Baseline - Soft tissue swelling	1.75 (± 2.01)			
Baseline - Arthralgia	3.39 (± 2.53)			
Week 24 - Headache	1.91 (± 1.84)			
Week 24 - Excessive perspiration	2.31 (± 2.2)			
Week 24 - Fatigue	3.55 (± 2.43)			
Week 24 - Soft tissue swelling	1.8 (± 2.11)			
Week 24 - Arthralgia	3.25 (± 2.63)			
Week 48 - Headache	2.33 (± 2.15)			
Week 48 - Excessive perspiration	2.48 (± 2.17)			
Week 48 - Fatigue	3.42 (± 2.31)			
Week 48 - Soft tissue swelling	2.07 (± 2.28)			
Week 48 - Arthralgia	3.69 (± 2.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Changes From Baseline in Quality of Life Scores (AcroQoL)

End point title	Mean Changes From Baseline in Quality of Life Scores (AcroQoL)

End point description:
ITT population.

AcroQoL score groups 22 components: Eight physical, Seven psychological appearance and Seven

psychological personal relations, adjusted to a scale of 100, where a score of 100 corresponds to the best possible QoL and 0 to the worst.

Only subjects from countries having a validated translation of the AcroQoL questionnaire (The Netherlands, Denmark, Sweden, France, Greece, Poland,
South Korea, Brazil, Russia, Norway and Romania) were included

End point type	Secondary

End point timeframe:

At weeks 24 and 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Units on a scale				
arithmetic mean (standard deviation)				
At week 24 (N=86)	-0.35 (± 11.43)			
At week 48 (N=83)	-1.08 (± 10.15)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Changes From Baseline in Quality of Life Scores (SF-36)

End point title	Mean Changes From Baseline in Quality of Life Scores (SF-36)

End point description:

ITT population.

Short Form-36 questionnaire (SF-36) score comprises eight components: Physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health on a scale of 100, where a score of 100 corresponds to the best possible QoL and 0 to the worst.

N = Number of subjects at the visit. Phase 1 only: These 15 subjects participated only in phase 1 and did not move on to phase 2.

End point type	Secondary

End point timeframe:

At weeks 24 and 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Units on a scale				
arithmetic mean (standard deviation)				
At week 24 (N=112)	1.03 (± 15.89)			
At week 48 (N=107)	0.06 (± 13.93)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Normalized IGF-1 Levels (Age and Sex Adjusted), Without Any Worsening of the AcroQoL Change Score Between Inclusion and Week 48

End point title	Percentage of Subjects With Normalized IGF-1 Levels (Age and Sex Adjusted), Without Any Worsening of the AcroQoL Change Score Between Inclusion and Week 48

End point description:

MITT population.

The criterion for a subject is satisfied if he had a IGF-1 level (age and sex adjusted) without any worsening of the AcroQoL change score between Inclusion and Week 48.

Only subjects from countries having a validated translation of the AcroQoL questionnaire (The Netherlands, Denmark, Sweden, France, Greece, Poland, South Korea, Brazil, Russia, Norway and Romania) were included.

End point type	Secondary

End point timeframe:

At week 48 (End of Study)

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	85			
Units: Percentage of subjects				
number (confidence interval 95%)				
Phase I / Group A (N=9)	44.4 (12 to 76.9)			
Phase I / Group B (N=55)	47.2 (33.7 to 60.6)			
Phase I / Group C (N=21)	38.1 (17.3 to 58.9)			
Overall study (N=85)	44.6 (33.9 to 55.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Correlation Between the Changes From Baseline in Quality of Life (AcroQoL) With the Corresponding Changes in IGF-1 Level (Expressed as % of ULN) at Each Visit

End point title	Correlation Between the Changes From Baseline in Quality of Life (AcroQoL) With the Corresponding Changes in IGF-1 Level (Expressed as % of ULN) at Each Visit

End point description:

ITT population. Only subjects from countries having a validated translation of the AcroQoL questionnaire (The Netherlands, Denmark, Sweden, France, Greece, Poland, South Korea, Brazil, Russia, Norway and Romania) were included.

AcroQoL change from Baseline to Week 24 (48) = AcroQoL at Week 24 (48) - AcroQoL at Baseline.

IGF-1 change from Baseline to Week 24 (48) = IGF-1 at Week 24 (48) - IGF-1 at Baseline.

Correlation presented is a Spearman correlation (non parametric).

N = Number of subjects at the visit.

Measure Type = Correlation

End point type	Secondary

End point timeframe:

At weeks 24 and 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	88			
Units: NA				
number (confidence interval 95%)				
Week 24: Phase I / Group A (n=8)	0.43 (-0.42 to 0.86)			
Week 24: Phase I / Group B (n=55)	-0.02 (-0.28 to 0.25)			
Week 24: Phase I / Group C (n=21)	-0.41 (-0.71 to 0.04)			
Week 24: Overall study (n=85)	-0.01 (-0.23 to 0.2)			
Week 48: Phase I / Group A (n=8)	0.69 (-0.08 to 0.93)			
Week 48: Phase I / Group B (n=53)	-0.06 (-0.32 to 0.22)			
Week 48: Phase I / Group C (n=21)	-0.09 (-0.5 to 0.35)			
Week 48: Overall study (n=82)	-0.01 (-0.22 to 0.21)			

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Growth Hormone (GH) Levels

End point title	Serum Growth Hormone (GH) Levels

End point description:

ITT population.

N= Number of subjects at the visit.

Phase 1 only: These 15 subjects participated only in phase 1 and did not move on to phase 2.

End point type	Secondary

End point timeframe:

At baseline, week 24 and week 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: ng/mL				
arithmetic mean (standard deviation)				
ITT - Baseline (N=124)	0.97 (± 1.09)			
ITT - Week 24 (N=112)	0.99 (± 1.42)			
ITT - Week 48 (N=107)	0.92 (± 0.87)			
MITT - Baseline (N=109)	0.96 (± 1.11)			
MITT - Week 24 (N=109)	0.88 (± 0.78)			
MITT - Week 48 (N=107)	0.92 (± 0.87)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With GH Level Less Than or Equal to 2.5 ng/mL

End point title	Percentage of Subjects With GH Level Less Than or Equal to 2.5 ng/mL

End point description:

End point type	Secondary

End point timeframe:

At weeks 24 and 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Percentage of subjects				
number (confidence interval 95%)				
ITT: Week 24 - Phase I only (n=15)	66.7 (13.3 to 100)			
ITT: Week 24 - Phase I / Group A (n=13)	100 (100 to 100)			
ITT: Week 24 - Phase I / Group B (n=70)	91.4 (84.9 to 98)			
ITT: Week 24 - Phase I / Group C (n=26)	100 (100 to 100)			

ITT: Week 24 - Overall study (n=124)	93.8 (89.3 to 98.2)			
ITT: Week 48 - Phase I / Group A (n=13)	100 (100 to 100)			
ITT: Week 48 - Phase I / Group B (n=70)	92.6 (86.4 to 98.9)			
ITT: Week 48 - Phase I / Group C (n=26)	96.2 (88.8 to 100)			
ITT: Week 48 - Overall study (n=124)	94.4 (90 to 98.8)			
MITT: Week 24 - Phase I / Group A (n=13)	100 (100 to 100)			
MITT: Week 24 - Phase I / Group B (n=70)	91.4 (84.9 to 98)			
MITT: Week 24 - Phase I / Group C (n=26)	100 (100 to 100)			
MITT: Week 24 - Overall study (n=109)	94.5 (90.2 to 98.8)			
MITT: Week 48 - Phase I / Group A (n=13)	100 (100 to 100)			
MITT: Week 48 - Phase I / Group B (n=70)	92.6 (86.4 to 98.9)			
MITT: Week 48 - Phase I / Group C (n=26)	96.2 (88.8 to 100)			
MITT: Week 48 - Overall study (n=109)	94.4 (90 to 98.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Subject Treatment Schedule Preference

End point title	Subject Treatment Schedule Preference

End point description:

ITT population.

At week 24, the preference assessed between Octreotide Long Acting Repeatable intramuscular injection (Oct-LAR IM)
every 4 weeks and Lanreotide Autogel 120 mg subcutaneous injection (SC) every 6 weeks.
At week 48, the preference is assessed between Oct-LAR IM every 4 weeks and Lanreotide Autogel 120 mg SC either
injected every 4, 6 or 8 weeks (as injected during Phase II of the study).

Lan: Lanreotide

W: Week

Inj: Injection

Wks: Weeks

Phs: Phase

Grp: Group

evy: every

End point type	Secondary

End point timeframe:
At weeks 24 and 48

End point values	Overall Study			
Subject group type	Subject analysis set			
Number of subjects analysed	124			
Units: Percentage of subjects				
number (not applicable)				
W24:Oct-LAR IM inj evy 4 wks Phs 1 only (n=15)	20			
W24:Lan Autogel inj evy 6 wks Phs 1 only (n=15)	80			
W24:Oct-LAR IM inj evy 4 wks Phs 1/Grp A(n=13)	7.7			
W24:Lan Autogel inj evy 6 wks Phs 1/Grp A(n=13)	92.3			
W24:Oct-LAR IM inj evy 4 wks Phs 1/Grp B(n=70)	10.3			
W24:Lan Autogel inj evy 6 wks Phs 1/Grp B(n=70)	85.3			
W24:Non precised Phs 1/Grp B (n=70)	4.4			
W24:Oct-LAR IM inj evy 4 wks Phs 1/Grp C(n=26)	3.8			
W24:Lan Autogel inj every 6 wks Phs 1/Grp C (n=26)	96.2			
W24:Oct-LAR IM inj evy 4 wks-Overall study(n=124)	8.9			
W24:Lan Autogel inj evy 6 wks-Overall study(n=124)	88.4			
W24: Non precised - Overall study (n=124)	2.7			
W48:Oct-LAR IM inj evy 4 wks Phs 1/Grp A(n=13)	15.4			
W48:Lan Autogel inj evy 6 wks Phs 1/Grp A(n=13)	76.9			
W48:Non precised Phs 1/Grp A (n=13)	7.7			
W48:Oct-LAR IM inj evy 4 wks Phs 1/Grp B(n=70)	14.7			
W48:Lan Autogel inj evy 4 wks Phs 1/Grp B(n=70)	1.5			
W48:Lan Autogel inj evy 6 wks Phs 1/Grp B(n=70)	77.9			
W48:Non precised Phs 1/Grp B (n=70)	5.9			
W48:Oct-LAR IM inj evy 4 wks Phs 1/Grp C(n=26)	7.7			
W48:Lan Autogel inj evy 8 wks Phs 1/Grp C(n=26)	92.3			
W48:Oct-LAR IM inj evy 4 wks-Overall study(n=124)	13.1			
W48:Lan Autogel inj evy 4 wks-Overall study(n=124)	10.3			
W48:Lan Autogel inj evy 6 wks-Overall study(n=124)	49.5			
W48:Lan Autogel inj evy 8 wks-Overall study(n=124)	22.4			

W48:Non precised-Overall study (n=124)	4.7			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: Up to week 48	
Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	13.0
Reporting groups	
Reporting group title	Phase 1: Lanreotide Autogel 120 mg
Reporting group description: -	
Reporting group title	Phase 2 (Group A): Lanreotide Autogel 120 mg
Reporting group description: -	
Reporting group title	Phase 2 (Group B): Lanreotide Autogel 120 mg
Reporting group description: -	
Reporting group title	Phase 2 (Group C): Lanreotide Autogel 120 mg
Reporting group description: -	

Serious adverse events	Phase 1: Lanreotide Autogel 120 mg	Phase 2 (Group A): Lanreotide Autogel 120 mg	Phase 2 (Group B): Lanreotide Autogel 120 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 15 (20.00%)	2 / 13 (15.38%)	4 / 70 (5.71%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Meningioma			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain contusion			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Varicose vein			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest Pain			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash papular			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			

subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 2 (Group C): Lanreotide Autogel 120 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 26 (7.69%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningioma			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Brain contusion			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Varicose vein			

subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest Pain			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			

subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash papular			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Phase 1: Lanreotide Autogel 120 mg	Phase 2 (Group A): Lanreotide Autogel 120 mg	Phase 2 (Group B): Lanreotide Autogel 120 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 15 (80.00%)	10 / 13 (76.92%)	49 / 70 (70.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma of liver			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Leiomyoma			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 15 (6.67%)	1 / 13 (7.69%)	1 / 70 (1.43%)
occurrences (all)	1	1	1
Hypotension			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	1 / 70 (1.43%)
occurrences (all)	0	1	1
Flushing			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Lymphangiectasia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Injection site pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	6 / 70 (8.57%)
occurrences (all)	0	0	15
Application site pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	0	4
Injection site induration			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	1	0	2
Nodule			

subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	2	0	3
Influenza like illness			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	0	4
Injection site nodule			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Asthenia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Chest pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	2	0	0
Feeling cold			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Injection site haematoma			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Injection site swelling			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Medical device pain			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Thirst			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Metrorrhagia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	1	0	1
Asthma			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Epistaxis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Nasal disorder			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Pleurisy			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Sleep apnoea syndrome			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Psychiatric disorders			
Alcoholism			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Anxiety			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Stress			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Investigations			
Blood pressure systolic decreased			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
High density lipoprotein increased			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Low density lipoprotein increased			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			

Arthropod bite			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Cardiac disorders			
Sinus bradycardia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 15 (6.67%)	2 / 13 (15.38%)	2 / 70 (2.86%)
occurrences (all)	1	2	2
Dizziness			
subjects affected / exposed	2 / 15 (13.33%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	2	0	1
Migraine			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	3	0	0
Carotid artery stenosis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Dysgeusia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Intercostal neuralgia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	1 / 70 (1.43%)
occurrences (all)	0	1	1
Bicytopenia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Leukopenia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Neutropenia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Eye disorders			
Cataract cortical			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Diplopia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Eye swelling			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Presbyopia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	11 / 70 (15.71%)
occurrences (all)	0	0	21
Abdominal pain			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	4 / 70 (5.71%)
occurrences (all)	0	0	8
Flatulence			
subjects affected / exposed	2 / 15 (13.33%)	0 / 13 (0.00%)	2 / 70 (2.86%)
occurrences (all)	2	0	2
Abdominal discomfort			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	3
Abdominal pain upper			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	2 / 70 (2.86%)
occurrences (all)	1	0	2
Dyspepsia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	2 / 70 (2.86%)
occurrences (all)	0	1	2
Nausea			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	1	0	1
Constipation			
subjects affected / exposed	2 / 15 (13.33%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	2	0	0
Abdominal distension			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	3
Dental caries			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Hiatus hernia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Proctitis			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Steatorrhoea			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 15 (6.67%)	2 / 13 (15.38%)	7 / 70 (10.00%)
occurrences (all)	2	3	7
Gallbladder polyp			
subjects affected / exposed	0 / 15 (0.00%)	2 / 13 (15.38%)	0 / 70 (0.00%)
occurrences (all)	0	2	0
Hepatomegaly			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	1 / 70 (1.43%)
occurrences (all)	0	1	1
Hepatic cyst			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Hepatic steatosis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	2 / 70 (2.86%)
occurrences (all)	0	1	2
Hyperhidrosis			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	1	0	1
Increased tendency to bruise			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	2
Seborrhoea			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Swelling face			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Renal cyst			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Calculus ureteric			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Nephrocalcinosis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Endocrine disorders			
Goitre			

subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Hypogonadism			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Hypothyroidism			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	3 / 70 (4.29%)
occurrences (all)	0	1	5
Osteoarthritis			
subjects affected / exposed	0 / 15 (0.00%)	2 / 13 (15.38%)	0 / 70 (0.00%)
occurrences (all)	0	2	0
Back pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Muscular weakness			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0
Myalgia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 15 (0.00%)	2 / 13 (15.38%)	3 / 70 (4.29%)
occurrences (all)	0	3	3
Urinary tract infection			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	0	5
Respiratory tract infection			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Bronchitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Cervicitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Dengue fever			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Fungal infection			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	2
Furuncle			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	2
Gastrointestinal viral infection			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Pulpitis dental			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Viral infection			

subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Dyslipidaemia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	6 / 70 (8.57%)
occurrences (all)	1	0	7
Impaired fasting glucose			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	5 / 70 (7.14%)
occurrences (all)	0	0	5
Diabetes mellitus			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	2 / 70 (2.86%)
occurrences (all)	1	0	2
Hypercholesterolaemia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	0	2
Hyperglycaemia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	1	0	1
Decreased appetite			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Diabetes mellitus inadequate contr			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	0	1
Fluid retention			
subjects affected / exposed	0 / 15 (0.00%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Hypoglycaemia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 13 (0.00%)	0 / 70 (0.00%)
occurrences (all)	1	0	0
Podagra			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	2	0

Type 2 diabetes mellitus			
subjects affected / exposed	0 / 15 (0.00%)	1 / 13 (7.69%)	0 / 70 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	Phase 2 (Group C): Lanreotide Autogel 120 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 26 (76.92%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma of liver			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Leiomyoma			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	2		
Hypotension			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Flushing			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Lymphangiectasia			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
General disorders and administration site conditions			
Injection site pain			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	7		
Application site pain			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Injection site induration			

subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	2			
Nodule				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	2			
Influenza like illness				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Injection site nodule				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Pyrexia				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Asthenia				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Chest pain				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Facial pain				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Fatigue				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Feeling cold				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Injection site haematoma				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Injection site swelling				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	2			
Malaise				

subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Medical device pain			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Thirst			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Metrorrhagia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Asthma			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Nasal disorder			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Pleurisy			

subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Sleep apnoea syndrome			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Alcoholism			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Stress			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Investigations			
Blood pressure systolic decreased			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
High density lipoprotein increased			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Low density lipoprotein increased			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Transaminases increased			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Weight decreased			

subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Sinus bradycardia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	5		
Dizziness			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Migraine			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Carotid artery stenosis			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Intercostal neuralgia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Sciatica			

subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Bicytopenia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Eye disorders			
Cataract cortical			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Diplopia			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Eye swelling			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Presbyopia			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Visual acuity reduced			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			

Diarrhoea				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	4			
Abdominal pain				
subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	4			
Flatulence				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Abdominal discomfort				
subjects affected / exposed	3 / 26 (11.54%)			
occurrences (all)	3			
Abdominal pain upper				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Dyspepsia				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Nausea				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Constipation				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Abdominal distension				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Dental caries				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Gastritis				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Gingivitis				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			

Hiatus hernia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1		
Proctitis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0		
Steatorrhoea subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 7		
Vomiting subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0		
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	4 / 26 (15.38%) 5		
Gallbladder polyp subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1		
Hepatomegaly subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0		
Hepatic cyst subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1		
Hepatic steatosis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0		
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0		
Hyperhidrosis subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1		
Increased tendency to bruise			

subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Rash pruritic			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Rosacea			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Seborrhoea			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Swelling face			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	2		
Renal cyst			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Calculus ureteric			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Haematuria			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Nephrocalcinosis			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Nephrolithiasis			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		

Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Hypogonadism			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Hypothyroidism			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Osteoarthritis			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		

Urinary tract infection				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Respiratory tract infection				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Bronchitis				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Cervicitis				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Dengue fever				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Fungal infection				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Furuncle				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Gastrointestinal viral infection				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Influenza				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Pulpitis dental				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
Rhinitis				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
Sinusitis				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			

Viral infection			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Dyslipidaemia			
subjects affected / exposed	3 / 26 (11.54%)		
occurrences (all)	3		
Impaired fasting glucose			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Diabetes mellitus			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Hypercholesterolaemia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Decreased appetite			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Diabetes mellitus inadequate contr			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Fluid retention			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Hypertriglyceridaemia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Hypoglycaemia			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Podagra			

subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported